Vialwirebiotech, curated
November 21, 2026, 6:00 AM
November 11, 2026
- 6:00 AM · Drug Discovery World6:00 AMFcRn inhibitor demonstrates sustained IgG reduction in Phase I trial — Drug Discovery World
- 5:42 AM · Pharmaceutical Technology5:42 AMProBio signs global antibody licensing deal with AbTis — Pharmaceutical Technology
- 5:00 AM · Drug Discovery World5:00 AMFirst clinical data for allogeneic CAR-T in autoimmune disease — Drug Discovery World
November 10, 2026
- 6:55 PM · STAT News
- 3:47 PM · TechCrunch
- 12:06 PM · BioPharma Dive12:06 PMBeam’s base editing therapy for sickle cell hits goal in pivotal trial — BioPharma Dive
- 11:00 AM · BioWorld11:00 AMImmunovant’s next-gen FcRn (re-)ascends in RA phase II — BioWorld
- 11:00 AM · BioWorld11:00 AMPepgen’s DM1 oligonucleotide shows ‘best-in-class’ potential — BioWorld
- 11:00 AM · BioWorld11:00 AMFDA clears Bayer’s Sunharbo as first factor XIa agent for stroke — BioWorld
- 11:00 AM · BioWorld11:00 AMAbbvie bets $1.47B-plus on Nxera’s EP4 agonist — BioWorld
- 11:00 AM · BioWorld11:00 AMFDA rejects Novocure’s TTFields device over clinical benefit — BioWorld
- 10:00 AM · PharmaVoice10:00 AMGondolaBio gives new meaning to ‘sweat equity’ in rare R&D — PharmaVoice
- 9:09 AM · PharmaVoice9:09 AMPfizer’s comeback gets a new finance chief — PharmaVoice
- 9:04 AM · Drug Discovery World9:04 AMPreliminary data indicate durable responses for combo cancer therapy — Drug Discovery World
- 8:38 AM · STAT News8:38 AMSTAT+: Dutch antitrust regulators probe Biogen over test for its MS drug — STAT News
- 8:00 AM · BioWorld8:00 AMSIM-0709 cleared to enter clinic for inflammatory bowel disease — BioWorld
- 8:00 AM · BioWorld8:00 AMSpruce Biosciences spins out CAH program into new subsidiary — BioWorld
- 8:00 AM · BioWorld8:00 AMViacure advances antibody therapy for type 2 diabetes — BioWorld
- 8:00 AM · BioWorld8:00 AMRibo announces EU CTA filing for SR-122 for dyslipidemia — BioWorld
- 7:05 AM · STAT News7:05 AMSTAT+: PepGen says early trial for muscular dystrophy drug looks promising — STAT News
- 5:22 AM · Pharmaceutical Technology5:22 AMDelix Therapeutics raises $100m for zalsupindole development — Pharmaceutical Technology
- 5:00 AM · Drug Discovery World5:00 AMBiotech raises a €31.5m seed round to develop mRNA therapeutics — Drug Discovery World
- 4:41 AM · Pharmaceutical Technology4:41 AMCharles River agrees $470m deal for Frontage assets — Pharmaceutical Technology
- 4:00 AM · Drug Discovery World4:00 AMFirst patient receives mRNA immunotherapy for ovarian cancer — Drug Discovery World
- 12:01 AM · BioPharma Dive12:01 AMBIO unveils plan for US to remain biotech’s ‘global leader’ — BioPharma Dive
November 9, 2026
- 7:50 PM · STAT News
- 7:00 PM · Nature Biotechnology7:00 PMSilence snapped up for $1.3 billion — Nature Biotechnology
- 7:00 PM · Nature Biotechnology7:00 PMChina plans ban on biotech exports — Nature Biotechnology
- 5:40 PM · BioPharma Dive5:40 PMBayer wins FDA nod for a new kind of blood thinner — BioPharma Dive
- 3:51 PM · STAT News
- 12:26 PM · Drug Discovery World12:26 PMLonza signs agreement to acquire US CDMO network from Merck — Drug Discovery World
- 12:20 PM · FT — Pharmaceuticals12:20 PMUS regulator orders makers of weight-loss drugs to carry blindness risk warning — FT — Pharmaceuticals
- 11:00 AM · BioWorld11:00 AMUS FDA warns of GLP-1 risk, weighs AAV malignancy risk — BioWorld
- 11:00 AM · BioWorld11:00 AMCMS’ Medicare negotiations transition from guidance to rule — BioWorld
- 11:00 AM · BioWorld11:00 AMVir’s combo approach nails phase III endpoints in hepatitis D trial — BioWorld
- 11:00 AM · BioWorld11:00 AMEntropy's IV psilocybin moves toward precision psychiatry — BioWorld
- 11:00 AM · BioWorld11:00 AMArgenx adds peptide discovery engine with Unnatural Products M&A — BioWorld
- 9:30 AM · STAT News
- 8:00 AM · BioWorld8:00 AMPierre Fabre and Xtalpi enter drug discovery collaboration — BioWorld
- 8:00 AM · BioWorld8:00 AMRegeneron presents REGN-22044 preclinical data at The Liver Meeting — BioWorld
- 8:00 AM · BioWorld8:00 AMCantargia’s CAN-14 targets IL-17 as well as IL1RAP — BioWorld
- 8:00 AM · BioWorld8:00 AMIdel Therapeutics and Daiichi Sankyo evaluate multidrug conjugate — BioWorld